Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: Expression of IL-12 in human tumor cells

Gene Therapy

Volumn 4, Issue 4, 1997, Pages 367-374

  Zhang, J ^a   Asselin Paturel, C ^b   Bex, F ^a   Bernard, J ^c   Chehimi, J ^d   Willems, F ^a   Caignard, A ^b   Berglund, P ^e   Liljestrom P ^e   Burny, A ^a   Chouaib, S ^b,f  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT JEAN GODINOT   (France)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f INSERM   (France)

Author keywords

Gene therapy; Human IL 12; Human tumor cells; SFV vector

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 12; MESSENGER RNA;

ANIMAL CELL; ARTICLE; ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA TRANSCRIPTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEMLIKI FOREST ALPHAVIRUS; TUMOR CELL LINE; VIRUS PARTICLE; VIRUS RECOMBINANT;

EID: 8244238389     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300409     Document Type: Article

References (32)

1. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1993; 15: 48-51.
2. Kobayashi M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-844.
3. Stern AS et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808-6812.
4. Gubler U et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991; 88: 4143-4147.
5. D'Andrea A et al. Production of natural killer cell stimulatory factor (NKSF/IL-12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-1398.
6. Desai BB et al. The IL-12 receptor. II. Distribution and regulation of receptor expression J Immunol 1992; 148: 3125-3132.
7. Chua AO et al. Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor super-family with strong homologv to gp130. J Immunol 1994; 153: 128-136.
8. Manetti R et al. Natural killer cell stimulator factor (NKSF/IL-12) induces Th1-type specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 1993; 177: 1199-1204.
9. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
10. Chan SH et al. Induction of IFNγ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
11. Gately MK et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFNγ in vivo. Int Immunol 1994; 6: 157-167.
12. Brunda MJ et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 1123-1130.
13. Voest EE et al. Interleukin-12 inhibits angiogenesis in vivo. J Natl Cancer Inst 1995; 87: 581-588.
14. Tahara H et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-189.
15. Mulligan RC. The basic science of gene therapy. Science 1993; 200: 926-932.
16. Tahara H et al. Effective eradication of established murine tumors with interleukin-12 (IL-12) gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
17. Rosenberg SA et al. Gene transfer into humans. Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. New Engl J Med 1990; 323: 570-578.
18. Gansbacher B et al. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res 1990; 50: 7820-7825.
19. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 1991; 9: 1356-1361.
20. Liljeström P. Alphavirus expression systems. Curr Opin Bictechnol 1994; 5: 495-500.
21. Mossman SP et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996; 70: 1953-1960.
22. Zhou X et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994; 12: 1510-1514.
23. Zhou X et al. Generation of cytotoxic and humoral immune responses using non-replicative recombinant Semliki Forest virus. Proc Natl Acad Sci USA 1995; 92: 3009-3013.
24. Gansbacher B et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
25. Chouaib S, Escudier B, Chehimi J. Interleukin-12, cellular and molecular immunology of an important regulatory cytokine. Eur Cytok Netw 1996; 7: 79-81.
26. Zeh HJ III, Hurd S, Storkus WJ, Lotze MT. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implication for the immunotherapy of cancer. J Immunother 1993; 14: 155-161.
27. Anderson WF. Human gene therapy. Science 1992; 256: 808-813.
28. Mattner F et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993; 23: 2202-2208.
29. Yang Y, Li Q, Ertl HC, Wilson J. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
30. Berglund P et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Bio/Technology 1993; 11: 916-920.
31. Chouaib S et al. Interleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994; 91: 12659-12663.
32. Kaufman RJ et al. Improved vectors for stable expression of foreign genes mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res 1991; 19: 4484-4492.